EE268 Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma
| Autor: | Garcia-Horton, V., Zhou, Z.Y., Moshyk, A., Rosenblatt, L.C., Patel, D., Xin, Y., Wang, Q., Christensen, D., Palaia, J. |
|---|---|
| Zdroj: | In Value in Health June 2023 26(6) Supplement:S108-S108 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect